Company history

iOmx has been founded by Nisit Khandelwal, Philipp Beckhove, Patrick Baeuerle, Sebastian Meier-Ewert and Elmar Maier in March 2016. The Company has attracted leading international life science investors and closed a EUR 40 million Series A financing round only a few months after its inception. The proceeds will be used to advance proprietary product candidates up to initial clinical proof-of-concept.

Management

Apollon Papadimitriou
Apollon is the Chief Executive Officer. Apollon acted as Chief Development Officer at iOmx from 2017 until mid of 2019. He has a long-standing track record in biotherapeutics development and has significantly contributed to the development and launch of many biologics products. Before joining iOmx in 2017, he acted as Global Head Large Molecule Bioanalytical R&D and Pharmaceutical Sciences Site Head at Roche Innovation Center Munich. During his career at Roche, starting in 1997, Apollon held several leadership positions in Biologics R&D within Pharma Research and Early Development and has been a key contributor to the foundation, build-up and evolution of Roche´s global large molecule research organization and pipeline. Apollon is a biologist by training and earned his PhD in Biochemistry in 1995 from the Julius-Maximilians-University of Würzburg, Germany. After a post-doctorate at the Institute for Experimental Cancer Research in Freiburg, Germany, he started his industrial career at Boehringer Mannheim in 1996 as a Senior Scientist in Biotechnology Research.
read more
Nisit Khandelwal
Nisit is the scientific co-founder of iOmx and serves as its Senior Vice-President, Research. Prior to joining iOmx, Nisit served as PI for a joint research project between the German Cancer Research Center and Bayer Health Care from 2014-2016. He is a research-driven entrepreneur with a strong focus on target discovery and early-stage drug development in the field of cancer immunotherapy. He is the lead inventor on a portfolio of patents and author of high-impact scientific publications. Nisit completed his undergraduate degree in Biotechnology from Vellore Institute of Technology in India and obtained his Masters degree in Biomedical Sciences from the University of Edinburgh in U.K. In 2011, he joined the laboratory of Prof. Dr. Philipp Beckhove at the German Cancer Research Center (DKFZ) in Heidelberg, Germany as a Helmholtz Scholar for his doctoral thesis on high-throughput identification of novel immune-checkpoint molecules on tumors.
read more
Marcus Irsfeld
Marcus is the Chief Financial Officer. He has a long-standing track record in this position either as employee or freelancer in the life science industry. Over the last years, he has been supporting several biotech and MedTech companies in different maturity stages. In 2001, he started his career in the life science industry as CFO of ProCorde GmbH which merged with Trigen in 2006. He finally took over the responsibility for the whole Trigen Group as the sole member of the executive board of Trigen Holdings AG. Before joining ProCorde, Marcus worked in different industries, including financial controller in a German Chinese joint venture in the province Shandong in China. Marcus holds a degree in Business Administration from the University in Münster, Germany. Marcus was co-founder and CFO of Averitas Pharma Inc. (NJ) which was successfully sold to Gruenenthal.
read more

Supervisory Board

Gerald H. Moeller, Chairman of the Supervisory Board
Dr. Gerald Moeller has more than 40 years of management experience in the diagnostic, pharmaceutical and MedTech industries. From May 2002 to April 2014 he was an Investment Advisor to HBM Partners, Zug/Switzerland. As an active participant in the international healthcare / biotechnology sector Dr. Moeller served on the board of companies such as Bionostics Inc (Director), BRAHMS AG (Chairman); Definiens AG (Chairman); Febit AG (Chairman); Genticel SA (ViceChairman), Ikonisys Inc (Director); Illumina Inc (Director); MTM Laboratories AG (Chairman); Invendo-Medical GmbH (Chairman); Pelikan Inc (Chairman); PowderJect Pharmaceuticals Plc (Chairman); Strakan Ltd (Chairman); Vivacta Ltd (Director) and Sugen Inc (Director). Sugen Inc, PowderJect Plc; MTM Laboratories AG, BRAHMS AG, Vivacta Ltd, Bionostics Inc, Definiens AG and Invendo-Medical GmbH were successfully sold to large global HealthCare companies.

From 2003 to 2016 Dr Moeller also served as Chairman of FIND (Foundation for Innovative New Diagnostics), a PDP with the Bill and Melinda Gates Foundation. In May 2018 Dr Moeller resigned from the Board of Directors of Morphosys AG after 19 years of Service as Chairman. Today he serves on the Board of

4Sigma GmbH,Germany (Chairman); (Healthcare Services)
Ayoxxa AG, Germany (Chairman)
Sphingotec GmbH, Germany (ViceChairman)
4teen4 GmbH, Germany, (Director)
DIADEM DX, Italy, (Chairman)

Dr Möller cofounded Adrenomed AG, a Biopharmaceutical company, served as Vice Chairman, from 12/17 to 8/19 as CEO and since 12/19 as Director. From 1975-1998, Dr. Moeller held several senior level positions in Germany, Japan, USA and the Netherlands with Boehringer Mannheim, including: Head of R&D Diagnostics; President of Decentralized Diagnostics; CEO of Boehringer Mannheim Therapeutics; and Chief Technology Officer of Corange, the holding company of Boehringer Mannheim. In 1995 he became CEO of the worldwide Boehringer Mannheim Group, which generated sales of >$4 billion in 1997. Following the sale of Boehringer Mannheim Group to Roche in 1998, Dr. Moeller was named Head of Global Development and Strategic Marketing Pharmaceuticals, as well as a member of Roche’s Executive Committee. Dr. Moeller left Roche in December 1998. Dr. Moeller received his Ph.D. in Physical Chemistry from the University of Kiel, Germany. He is married with 2 children.
read more
Henrijette Richter, Vice-chairwoman
Henrijette Richter is Managing Partner at Sofinnova Partners, Paris. She joined in 2014 from Novo Seeds (part of Novo A/S) where she was involved in the establishment of the group in 2007. While at Novo Seeds Henrijette was instrumental in the creation, financing and building of companies such as Cytoguide, Orphazyme, Avilex Pharma, EpiTherapeutics (sold to Gilead) and Lysogene. Henrijette is a scientist by training and started her career at Novo Nordisk conducting her PhD in the area of obesity and GH signalling. Before joining Sunstone Capital in 2004, Henrijette was a postdoctoral fellow at the MIT Center for Cancer Research (MA). Henrijette is a member of WITH (Women innovating together in Healthcare) and she is a board member of Asceneuron (CH).
read more
Patrick A. Baeuerle
Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.

Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.

Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
read more
Shinichiro Fuse
Dr. Shinichiro (Shin) Fuse is focused on advancing MPM’s investment identification, due diligence and business development activities. Shin is an investment committee member of the UBS Oncology Impact Fund (OIF), an oncology-only crossover fund (both private and public equities) managed by MPM and supports MPM’s relationship with Astellas. Shin serves on the board of Triplet Therapeutics and Orna Therapeutics and is a board observer for CODA Biotherapeutics and was previously a board observer for Repare Therapeutics (RPTX). He previously served operational roles at portfolio companies as the interim CEO of Orna Therapeutics and interim SVP of Business Development at ElevateBio, where he led several deals including Allovir and HighPass Bio.
Prior to joining MPM, he was Director of Business Development at bluebird bio, where he was instrumental in executing and managing key industry and academic partnerships in the fields of cell and gene therapy, cancer immunotherapy and genome editing, including partnerships with the National Cancer Institute and the acquisition of Pregenen. Previously, he was at Campbell Alliance (Syneos Health) as a life science strategy consultant, and at PureTech Ventures, where he was a member of the founding team of Vedanta Biosciences. He also serves as a columnist for Nikkei Biotech, the leading biotech journal in Japan. Shin received his Ph.D. in Microbiology and Immunology from Dartmouth College, an M.S. in Biomedical Science from the University of Tokyo, and a B.Eng. in Applied Chemistry from Keio University in Japan.
read more
Rainer Strohmenger
Rainer Strohmenger is a Managing Partner at Wellington Partners and one of Europe’s most experienced venture capitalists in Life Sciences. His more than 22 years of investment activity have involved financing of some of the most successful European biotech, medtech, diagnostics and healthcare IT companies. In the late 1990s he co-managed Wellington’s investment in Swiss biotech player Actelion, which became the most successful venture-backed biopharmaceutical company in Europe and was acquired in 2017 by Johnson & Johnson for US$ 30 billion. He was also responsible for the investments in Definiens (acquired by Medimmune), Genkyotex (NYSE Euronext: GKTX), Grandis (acquired by Novartis), immatics (NASDAQ: IMTX), invendo medical (acquired by Ambu), mtm laboratories (acquired by Roche), NoemaLife (acquired by Dedalus), Oxford Immunotec (NASDAQ: OXFD) and Wavelight (acquired by Alcon). Prior to joining Wellington Partners, Rainer was involved in medical research with a primary focus on cardiovascular physiology and in research on health economics at the Ludwig-Maximilians-University in Munich, Germany. Rainer holds a M.D. in medicine as well as a M.Sc. in economics, both from Ludwig-Maximilians-University in Munich, Germany, and was trained at the Entrepreneurship Center of the MIT, Boston, USA. He is a Member of the VC Council at InvestEurope and a Member of the Senate at the German Association of Small and Medium-sized Businesses (BVMW).
read more
Philipp Beckhove
Philipp Beckhove, M.D., Ph.D., is the co-founder of iOmx Therapeutics and is currently the Director of Regensburg Center of Interventional Immunology (RCI) at University of Regensburg, Germany. As tumor immunologist, Philipp's scientific work focuses on translating basic immunological research into new therapies for oncology. Prior to joining RCI in 2015, Philipp headed the Division of Translational Immunology at the German Cancer Research Center in Heidelberg, Germany from 2011-2015. He specialized in internal medicine at the University of Heidelberg in 2009. As of 2009, Philipp also holds an adjunct Associate Professorship of Immunotherapy at the Comprehensive Cancer Center, Northwestern University, Chicago, U.S.A.
read more

Scientific advisory

iOmx will be supported by a high-profile team of reputed international scientists in the field of oncology, immunotherapy and clinical drug development who will serve on its Scientific Advisory Board (to be announced soon).

Philipp Beckhove, Chair of the Scientific Board
Philipp Beckhove, M.D., Ph.D., is the Director of Regensburg Center of Interventional Immunology (RCI) at University of Regensburg, Germany. As tumor immunologist, Philipp's scientific work focuses on translating basic immunological research into new therapies for oncology. Prior to joining RCI in 2015, Philipp headed the Division of Translational Immunology at the German Cancer Research Center in Heidelberg, Germany from 2011-2015. He specialized in internal medicine at the University of Heidelberg in 2009. As of 2009, Philipp also holds an adjunct Associate Professorship of Immunotherapy at the Comprehensive Cancer Center, Northwestern University, Chicago, U.S.A.
read more
Patrick A. Baeuerle
Patrick A. Baeuerle, Ph.D., joined MPM in 2015. Patrick is responsible for the development of BiTE antibody Blincyto® (blinatumomab; AMG 103) which was approved within three months by the US FDA for therapy of relapsed/refractory acute lymphoblastic leukemia. He also spearheaded the development of the BiTE technology, the industry- leading T-cell engaging antibody platform.

Prior to joining MPM, Patrick served as Vice President, Research, and General Manager, Amgen Research (Munich) GmbH, where he oversaw translational science as well as BiTE development. From 1998-2012, Patrick served as Chief Scientific Officer for Micromet, Inc., and earlier oversaw drug discovery at Tularik Inc., a publicly traded biotechnology company acquired by Amgen (AMGN). He also served as Professor and Chairman of Biochemistry and Molecular Biochemistry at the Medical Faculty of Freiburg University, Germany, and did seminal research on transcription factor NF-kappaB at the Gene Center in Martinsried, Germany.

Patrick was rated Germany’s most frequently cited biomedical scientist of the decade (1990-1999), and among the top 50 worldwide (1990-1997). A recipient of numerous awards, he holds a Ph.D. in biology from the University of Munich, and performed post-doctoral research with Dr. David Baltimore at the Whitehead Institute of the Massachusetts Institute of Technology. He is also an Honorary Professor of Immunology of the Medical Faculty at Munich University.
read more